EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Embecta Corp.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.21−0.06 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $363.36M
- P/E (TTM)
- 4.2
- Dividend yield
- 9.66%
Embecta Corp. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Pen Needles | $784.10M | $844.40M | $829.20M | $824.60M | – | – | 72.6% | -7.1% |
| Safety | $137.80M | $129.40M | $126.30M | $119.60M | – | – | 12.8% | +6.5% |
| Syringes | $124.60M | $126.20M | $138.10M | $156.00M | – | – | 11.5% | -1.3% |
| Contract Manufacturing | $19.90M | $12.80M | $13.00M | $15.00M | – | – | 1.8% | +55.5% |
| Other | $14.00M | $10.30M | $14.20M | $14.30M | – | – | 1.3% | +35.9% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| United States | $579.10M | $607.20M | $601.40M | $600.30M | $609.40M | $563.00M | 53.6% | -4.6% |
| International | $501.30M | $515.90M | $519.40M | $529.20M | $555.90M | $522.50M | 46.4% | -2.8% |
From the segment and revenue-disaggregation notes of Embecta's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.